Bank of Montreal Can Lowers Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Bank of Montreal Can decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 40.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 42,948 shares of the biotechnology company’s stock after selling 28,701 shares during the quarter. Bank of Montreal Can’s holdings in United Therapeutics were worth $13,740,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in UTHR. Evergreen Capital Management LLC purchased a new stake in shares of United Therapeutics during the second quarter worth $375,000. HighVista Strategies LLC acquired a new position in United Therapeutics during the 2nd quarter worth approximately $449,000. Epoch Investment Partners Inc. increased its position in shares of United Therapeutics by 6.2% in the 2nd quarter. Epoch Investment Partners Inc. now owns 226,655 shares of the biotechnology company’s stock valued at $72,201,000 after purchasing an additional 13,157 shares during the last quarter. 1832 Asset Management L.P. acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at $1,562,000. Finally, Profund Advisors LLC lifted its position in shares of United Therapeutics by 73.1% during the 2nd quarter. Profund Advisors LLC now owns 12,638 shares of the biotechnology company’s stock worth $4,026,000 after purchasing an additional 5,338 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $320.45, for a total value of $1,153,620.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $41,658.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $320.45, for a total transaction of $1,153,620.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $41,658.50. The disclosure for this sale can be found here. Insiders have sold a total of 111,252 shares of company stock valued at $36,939,427 over the last quarter. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Stock Up 0.2 %

United Therapeutics stock opened at $358.53 on Friday. The stock has a 50 day moving average of $342.08 and a two-hundred day moving average of $295.69. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08. The stock has a market capitalization of $15.95 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 1.29 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. United Therapeutics’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the prior year, the business earned $5.24 earnings per share. As a group, research analysts expect that United Therapeutics Co. will post 24.84 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on UTHR. Oppenheimer upped their price objective on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. Jefferies Financial Group lifted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 price objective on shares of United Therapeutics in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $357.17.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.